Competitiveness as compared to which drug? Since it's only in phase 2, it's so far not in a position to be competitive. But the science seems sound, as far as that goes. In vitro testing suggests that a high level of expression of PSMA is more likely to be associated with drug efficacy. The ADC showed a high level of activity against PC xenografts. I beleive there is a companion imaging compound as well.
The limited phase I data available didn't suggest the drug is a home run, but interesting activity was seen as reflected by decreases in PSA and CTCs. Neutropenia may be a concern.
Compared to MDVN, etc. I wasn't too impressed with results so far but I wonder if it could be used for a subset of patients that don't respond to MDVN drug and others. I believe PSMA had also been targeted before without success but maybe by naked antibodies. I thought there is also some controversy with correlation of PSA with drug efficacy for PC.